When to Start Planning for a Pre-BLA / Pre-NDA Meeting

Why This Meeting Matters More Than Teams Expect

For many first-time sponsors, the Pre-NDA or Pre-BLA meeting is viewed as a checkpoint—something that happens shortly before submission to confirm readiness. In reality, this meeting is far more strategic than it appears.

It is one of the last structured opportunities to align with FDA before submitting your application. The questions you ask—and how well you prepare for the discussion—can directly influence your submission strategy, the clarity of your data presentation, and even the likelihood of review delays.

Teams that treat this meeting as a late-stage formality often miss its full value. The most effective sponsors approach it as a critical milestone that requires thoughtful preparation well in advance.

When Pre-BLA/Pre-NDA Meeting Planning Should Actually Begin

One of the most common mistakes is starting too late.

Planning for a Pre-BLA or Pre-NDA meeting should typically begin during Phase 3—not after all data are finalized. In many cases, initial planning starts as key trial designs are locked and major endpoints are defined.

Early planning allows teams to:

• Identify the most important strategic questions for the FDA

• Align internally on key interpretations of the data

• Anticipate potential areas of regulatory concern.

Waiting until the submission timeline is already compressed limits your ability to ask meaningful questions and incorporate FDA feedback effectively.

What Questions Are Worth Asking FDA

Not all questions are equally valuable in a Pre-NDA/BLA meeting. The most effective questions are those that:

• Address areas of uncertainty that could impact approval

• Clarify expectations for data presentation or analyses

• Confirm alignment on endpoints, populations, or labeling strategy

Examples include:

• Whether your proposed primary endpoint supports the intended indication

• How FDA expects certain subgroup analyses to be presented

• Whether specific datasets or formats meet reviewer expectations

Strong questions are focused, strategic, and tied directly to decisions your team needs to make before submission.

What Not to Ask (and Why It Matters)

Equally important is knowing what not to ask. Questions that are overly broad, hypothetical, or already addressed in guidance documents can dilute the impact of your meeting. For example:

• Asking FDA to “confirm overall approvability”

• Submitting long lists of low-priority or technical formatting questions

• Raising issues that are not yet fully developed internally

  
  

These types of questions can reduce the clarity of the discussion and make it harder to get meaningful feedback on critical topics. A focused, well-prioritized question set leads to a more productive meeting and clearer outcomes.

Practical Steps to Prepare Effectively

1. Start with internal alignment.

Before drafting questions, ensure cross-functional agreement on key data interpretations, risks, and proposed strategies.

2. Prioritize your questions.

Limit your list to the topics that will meaningfully influence submission decisions. Quality matters far more than quantity.

3. Draft clear, specific questions.

Well-structured questions lead to clearer FDA responses. Avoid ambiguity wherever possible.

4. Prepare concise briefing materials.

Your meeting package should clearly explain the context behind each question without overwhelming reviewers with unnecessary detail.

5. Rehearse the discussion.

Internal dry runs help ensure that presenters are aligned and that key messages come through clearly during the actual meeting.

6. Plan for how you will use the feedback.

Think ahead about how different FDA responses will influence your submission strategy so you can act quickly after the meeting.

Turning the Meeting into a Strategic Advantage

When approached thoughtfully, the Pre-NDA/BLA meeting becomes more than a regulatory requirement—it becomes a strategic tool.

Sponsors who prepare early and ask the right questions are better positioned to:

• Reduce uncertainty heading into submission

• Align expectations with FDA reviewers

• Provide validated outputs suitable for FAERS submission

Now is the time to confirm the Agency's thinking. For example, do you know that instead of assuming and relying on general guidance or experience, you can ask specific Format and Content questions that outline the contents of your specific submission, including what references, datasets, narratives, and CRFs you'll need to include? Sometimes these expectations can be specific to your program and reviewing team, and alignment can save you a ton of time.

Just like the NDA/BLA preparation, the value of the Pre-NDA/BLA meeting is directly tied to the quality of the preparation behind it. And like most things we do in Regulatory, the devil of the meeting is in the details. But the good thing is, you are not alone. Many before you have been there and done that, both successfully and not successfully. So there are plenty of resources, guidance, and experience to pull from.

The SWOT team has over 80+ years of Regulatory and Regulatory Operations experience, including preparing the Pre-Meeting Package and determining what operational questions you may be mistaken in leaving unanswered. If you would like to pressure test your thinking with our team, note we are only an email away at info@sugarwaterops.com. Let the Ops Team in the cubicle next door help you.